Shanghai Qilu Pharmaceutical Research and Development Centre describes new PKMYT1 inhibitors
June 19, 2024
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has identified membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.